118 related articles for article (PubMed ID: 29061330)
1. A French point of view about the cost effectiveness of RASQ61R immunohistochemistry in colorectal cancer.
Uguen A
Pathology; 2017 Dec; 49(7):810-811. PubMed ID: 29061330
[No Abstract] [Full Text] [Related]
2. New Guideline on Managing Colorectal Cancer.
Cancer Discov; 2017 Apr; 7(4):OF2. PubMed ID: 28249840
[TBL] [Abstract][Full Text] [Related]
3. Real-Life Distribution of KRAS and NRAS Mutations in Metastatic Colorectal Carcinoma from French Routine Genotyping.
Piton N; Lonchamp E; Nowak F; Sabourin JC;
Cancer Epidemiol Biomarkers Prev; 2015 Sep; 24(9):1416-8. PubMed ID: 26189770
[TBL] [Abstract][Full Text] [Related]
4. Mutation location on the RAS oncogene affects pathologic features and survival after resection of colorectal liver metastases.
Frankel TL; Vakiani E; Nathan H; DeMatteo RP; Kingham TP; Allen PJ; Jarnagin WR; Kemeny NE; Solit DB; D'Angelica MI
Cancer; 2017 Feb; 123(4):568-575. PubMed ID: 27737491
[TBL] [Abstract][Full Text] [Related]
5. Correlations of IGF-1R and COX-2 Expressions with Ras and BRAF Genetic Mutations, Clinicopathological Features and Prognosis of Colorectal Cancer Patients.
Jin M; Long ZW; Yang J; Lin X
Pathol Oncol Res; 2018 Jan; 24(1):45-57. PubMed ID: 28188432
[TBL] [Abstract][Full Text] [Related]
6. Detection of Rare Mutations by Routine Analysis of KRAS, NRAS, and BRAF Oncogenes.
Mikhailenko DS; Efremov GD; Safronova NY; Strelnikov VV; Alekseev BY
Bull Exp Biol Med; 2017 Jan; 162(3):375-378. PubMed ID: 28091917
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of RAS mutations and individual variation patterns among patients with metastatic colorectal cancer: A pooled analysis of randomised controlled trials.
Peeters M; Kafatos G; Taylor A; Gastanaga VM; Oliner KS; Hechmati G; Terwey JH; van Krieken JH
Eur J Cancer; 2015 Sep; 51(13):1704-13. PubMed ID: 26049686
[TBL] [Abstract][Full Text] [Related]
8. High Intra- and Inter-Tumoral Heterogeneity of RAS Mutations in Colorectal Cancer.
Jeantet M; Tougeron D; Tachon G; Cortes U; Archambaut C; Fromont G; Karayan-Tapon L
Int J Mol Sci; 2016 Dec; 17(12):. PubMed ID: 27916952
[TBL] [Abstract][Full Text] [Related]
9. The Usefulness of SP174 Anti-RASQ61R Immunohistochemistry in Melanoma, Thyroid, and Colorectal Cancers.
Uguen A
Arch Pathol Lab Med; 2017 Dec; 141(12):1601. PubMed ID: 29189061
[No Abstract] [Full Text] [Related]
10. Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine.
Grothey A; Sargent DJ
JAMA Oncol; 2016 Sep; 2(9):1133-4. PubMed ID: 27273467
[No Abstract] [Full Text] [Related]
11. RAS status in Korean patients with stage III and IV colorectal cancer.
Lee WS; Lee JN; Baek JH; Park YH
Clin Transl Oncol; 2015 Sep; 17(9):751-6. PubMed ID: 25997687
[TBL] [Abstract][Full Text] [Related]
12. Health-related quality of life in patients with metastatic colorectal cancer, association with systemic inflammatory response and RAS and BRAF mutation status.
Thomsen M; Guren MG; Skovlund E; Glimelius B; Hjermstad MJ; Johansen JS; Kure E; Sorbye H; Pfeiffer P; Christoffersen T; Guren TK; Tveit KM
Eur J Cancer; 2017 Aug; 81():26-35. PubMed ID: 28595137
[TBL] [Abstract][Full Text] [Related]
13. Challenging a dogma: co-mutations exist in MAPK pathway genes in colorectal cancer.
Grellety T; Gros A; Pedeutour F; Merlio JP; Duranton-Tanneur V; Italiano A; Soubeyran I
Virchows Arch; 2016 Oct; 469(4):459-64. PubMed ID: 27401719
[TBL] [Abstract][Full Text] [Related]
14. RAS testing in metastatic colorectal cancer: excellent reproducibility amongst 17 Dutch pathology centers.
Boleij A; Tops BB; Rombout PD; Dequeker EM; Ligtenberg MJ; van Krieken JH;
Oncotarget; 2015 Jun; 6(17):15681-9. PubMed ID: 25944693
[TBL] [Abstract][Full Text] [Related]
15. The RAS mutation status predicts survival in patients undergoing hepatic resection for colorectal liver metastases: The results from a genetic analysis of all-RAS.
Amikura K; Akagi K; Ogura T; Takahashi A; Sakamoto H
J Surg Oncol; 2018 Mar; 117(4):745-755. PubMed ID: 29194647
[TBL] [Abstract][Full Text] [Related]
16. [Examination of molecular markers used n the treatment of colon cancer].
DomagaĆa P; Kowalik A
Pol J Pathol; 2014 Dec; 65(4 Suppl 1):S59-77. PubMed ID: 26165036
[No Abstract] [Full Text] [Related]
17. Profiling circulating tumour cells and cell free DNA together in metastatic colon cancer.
Friend T; Stebbing J
Br J Cancer; 2021 Sep; 125(7):907-908. PubMed ID: 33953346
[TBL] [Abstract][Full Text] [Related]
18. Precision Therapy in RAS Mutant Colorectal Cancer.
Dienstmann R; Connor K; Byrne AT;
Gastroenterology; 2020 Mar; 158(4):806-811. PubMed ID: 31972237
[No Abstract] [Full Text] [Related]
19. Validating a fully automated real-time PCR-based system for use in the molecular diagnostic analysis of colorectal carcinoma: a comparison with NGS and IHC.
Colling R; Wang LM; Soilleux E
J Clin Pathol; 2017 Jul; 70(7):610-614. PubMed ID: 28292978
[TBL] [Abstract][Full Text] [Related]
20. Use of Liquid Biopsy in Monitoring Colorectal Cancer Progression Shows Strong Clinical Correlation.
Sun Q; Liu Y; Liu B; Liu Y
Am J Med Sci; 2018 Mar; 355(3):220-227. PubMed ID: 29549923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]